Holen Sie sich die Stockscreener-App
251.28
0.25%
0.36
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$250.92
Offen:
$252.92
24-Stunden-Volumen:
43,351
Relative Volume:
0.04
Marktkapitalisierung:
$36.68B
Einnahmen:
$5.26B
Nettoeinkommen (Verlust:
$1.44B
KGV:
25.72
EPS:
9.7713
Netto-Cashflow:
$1.76B
1W Leistung:
+2.75%
1M Leistung:
+2.04%
6M Leistung:
-1.73%
1J Leistung:
+6.51%
1-Tages-Spanne:
$250.51
$253.17
1-Wochen-Bereich:
$242.54
$253.17
52-Wochen-Spanne:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
251.31 | 36.63B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
586.11 | 207.41B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
204.13 | 58.46B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
79.89 | 39.60B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
42.66 | 32.47B | 27.43B | 1.27B | 1.01B | 1.5829 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus
Resmed director Farrell sells $497k in shares By Investing.com - Investing.com India
Resmed director Farrell sells $497k in shares - Investing.com
SG Americas Securities LLC Acquires 47,758 Shares of ResMed Inc. $RMD - MarketBeat
Robeco Institutional Asset Management B.V. Sells 11,596 Shares of ResMed Inc. $RMD - MarketBeat
ResMed officer Brett Sandercock discloses planned sale of 1,000 shares under trading plan - MSN
How ResMed Inc. (Common Stock) (RMEA) stock correlates with oil marketsWeekly Trend Summary & Weekly Return Optimization Plans - ulpravda.ru
Will ResMed Inc. stock gain from lower inflationJuly 2025 Catalysts & Expert Curated Trade Setups - ulpravda.ru
Why ResMed Inc. (RME) stock is listed among top recommendations2025 Short Interest & Accurate Trade Setup Notifications - ulpravda.ru
EV Market: How ResMed Inc. (Common Stock) (RMEA) stock correlates with oil marketsPortfolio Return Report & Pattern Based Trade Signal System - ulpravda.ru
Michael Farrell Sells 4,991 Shares of ResMed (NYSE:RMD) Stock - MarketBeat
Resmed Sets January 29 Date to Unveil Q2 FY2026 Results - TipRanks
ResMed CEO Michael Farrell Plans Further Insider Share Sale Under Rule 144 - TipRanks
Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 - The Manila Times
Resmed Insider Sold Shares Worth $1,240,065, According to a Recent SEC Filing - MarketScreener
Will ResMed Inc. stock deliver stable dividendsJuly 2025 Action & Verified Short-Term Plans - ulpravda.ru
How ResMed Inc. (RME) stock performs during market turbulenceQuarterly Trade Summary & Daily Growth Stock Investment Tips - ulpravda.ru
Is ResMed Inc. (RME) stock protected from inflationEntry Point & AI Enhanced Trading Alerts - ulpravda.ru
ResMed Officer Plans Further Share Sale Under Rule 144 - MSN
An excellent week for ResMed Inc.'s (NYSE:RMD) institutional owners who own 69% as one-year returns inch higher - Yahoo Finance
Resmed Receives FDA Clearance for AI-Personalized CPAP Mask Settings - San Diego Business Journal
Is This the Right Time to Add Resmed Stock to Your Portfolio? - TradingView — Track All Markets
ResMed Director Peter Farrell Plans Additional Insider Share Sale Under Rule 144 - TipRanks
ResMed CFO Sells Small Block of Shares Under Pre-Arranged Trading Plan - TipRanks
Insider at company (NYSE: RMD) files Rule 144 to sell 2,000 shares - Stock Titan
RMD (RMD) insider Michael Farrell files to sell 4,991 common shares - Stock Titan
Will ResMed Inc. stock attract more institutional investorsVolume Analysis Techniques & Outperform With Our Smart Trading Calculator - ulpravda.ru
The Truth About ResMed Inc: Sleep Tech Darling or Overhyped Dinosaur? - AD HOC NEWS
ResMed stock in focus: sleep-tech leader tests investor conviction after choppy start to the year - AD HOC NEWS
EBIT per share of Resmed Inc. – OTC:RSMDF - TradingView — Track All Markets
Global Sleep Tech Devices Market Poised for Strong Growth at a CAGR of ~17% by 2032, Driven by Rising Sleep Disorder Prevalence | DelveInsight - GlobeNewswire Inc.
ResMed updates CDI and share structure for December 2025 - MSN
Asset Management One Co. Ltd. Raises Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Updates CDI and Share Structure for December 2025 - TipRanks
Insider Sell: Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed (RMD) CFO discloses 1,000-share planned stock sale in Form 4 - Stock Titan
ResMed Executive Files Routine Rule 144 Notice for Small Share Sale - TipRanks
ResMed (NYSE:RMD) General Counsel Michael Rider Sells 50 Shares - MarketBeat
ResMed (RMD) Valuation Check As Investors Await Fiscal Q2 Earnings Update - Sahm
ResMed Inc (RMD) general counsel reports 50-share insider stock sale - Stock Titan
What you need to know ahead of ResMed's earnings release - MSN
ResMed Q2 2026 Earnings Preview: EPS Growth Forecast & Analyst Rating | BarchartNews and Statistics - IndexBox
ResMed Inc. $RMD Shares Sold by TriaGen Wealth Management LLC - MarketBeat
Railway Pension Investments Ltd Increases Position in ResMed Inc. $RMD - MarketBeat
What You Need to Know Ahead of ResMed's Earnings Release - Barchart.com
ResMed Inc. (RMD) Stock Analysis: Unveiling A 19.19% Potential Upside For Investors - DirectorsTalk Interviews
ResMed Inc.: How a Sleep-Tech Powerhouse Is Turning Data, Devices and Chronic Care Into a Platform P - AD HOC NEWS
Geopolitics Watch: Is ResMed Inc Common Stock RMEA stock overpriced at current multiplesWeekly Profit Summary & Weekly Return Optimization Plans - moha.gov.vn
ResMed Inc Reports Changes in CHESS Depositary Interests and Securities - MSN
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
ResMed Inc. (NYSE:RMD) is favoured by institutional owners who hold 69% of the company - simplywall.st
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):